Imago BioSciences is a San Francisco-based clinical development company dedicated to translating state-of-the art science into novel medicines for treating diseases that currently pose great challenges to patients, their families and their physicians. The company leverages the skills and extensive experience of its team and the financial commitment of its investors to focus on a small family of orphan diseases. Imago BioSciences translates unique insights into high impact transformative therapies that alter the natural history of disease allowing patients to live longer, disease-free lives.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/31/14 | $26,500,000 | Series A |
Amgen Business Development Clarus Ventures Frazier Healthcare Merck Research Labs Venture Fund | undisclosed |
| 03/21/19 | $40,000,000 | Series B |
Amgen Business Development Frazier Healthcare Partners Highlight Capital MRL Ventures Fund Omega Funds  Pharmaron | undisclosed |
